Trial Profile
Drug Use Investigation of Cervarix.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Aug 2023
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 23 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 06 Dec 2013 Planned end date changed from 1 Jun 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
- 12 Aug 2011 Actual initiation date 1 Sep 2010 added as reported by ClinicalTrials.gov.